人参皂苷的抗肝癌作用机制

doi:10.3760/cma.j.issn.1673-422X.2015.10.019

摘要/Abstract

摘要： 人参皂苷（GS）为人参的主要成分，包括Rg3、Rh2、Rd、Rh1、Rg2等数十种单体。GS及其各种单体抗肝癌机制各异，主要机制包括以下方面：诱导肝癌细胞凋亡、抑制肝癌细胞增殖、抑制肝癌细胞侵袭和转移、逆转肝癌细胞多药耐药、联合其他治疗手段的协同增效作用、提高机体免疫功能、抑制肝脏葡萄糖生成。不同的GS单体通过各自途径发挥不同的抗肝癌作用。

关键词: 人参皂甙类, 肝肿瘤, 中药药理学

Abstract: Ginsenosides (GS) as the main ingredient of ginseng, include dozens of monomer, such as Rg3, Rh2, Rd, Rh1, Rg2, etc. GS and various monomers have different antihepatoma mechanisms. The main mechanism includes the following aspects， inducing the apoptosis of liver cancer cells, inhibiting the proliferation, invasion and metastasis, reversing the multidrug resistance of liver cancer cells, increasing therapeutic effects by combining with other treatments, improving the immune function of organism and inhibiting hepatic glucose production. Different GS monomers play different roles of antihepatoma through their respective channels.

Key words: Ginsenosides, Liver neoplasms, Pharmacology

张娜,封颖璐. 人参皂苷的抗肝癌作用机制[J]. 国际肿瘤学杂志, 2015, 42(10): 786-788.

Zhang Na, Feng Yinglu. Anti-hepatoma mechanisms of ginsenoside[J]. Journal of International Oncology, 2015, 42(10): 786-788.

参考文献

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 69-90. ［2］ Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma［J］. Lancet, 2003, 362(9399): 1907-1917. ［3］ Guo XX, Guo Q, Li Y, et al. Ginsenoside Rh2 induces human hepatoma cell apoptosisvia bax/bak triggered cytochrome C release and caspase9/caspase8 activation［J］. Int J Mol Sci, 2012, 13(12): 15523-15535. ［4］ Park HM, Kim SJ, Kim JS, et al. Reactive oxygen species mediated ginsenoside Rg3 and Rh2induced apoptosis in hepatoma cells through mitochondrial signaling pathways［J］. Food Chem Toxicol, 2012, 50(8): 2736-2741. ［5］ Zhu GY, Li YW, Tse AK, et al. 20(S)Protopanaxadiol, a metabolite of ginsenosides, induced cell apoptosis through endoplasmic reticulum stress in human hepatocarcinoma HepG2 cells［J］. Eur J Pharmacol, 2011, 668(1-2): 88-98. ［6］ Zhang C, Liu L, Yu Y, et al. Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells［J］. Mol Med Rep, 2012, 5(5): 1295-1298. ［7］ Jiang JW, Chen XM, Chen XH, et al. Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway［J］. World J Gastroenterol, 2011, 17(31): 3605-3613. ［8］ Yoon JH, Choi YJ, Lee SG. Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogenactivated protein kinase signaling pathway in human hepatocellular carcinoma cells［J］. Eur J Pharmacol, 2012, 679(1-3): 24-33. ［9］ Yoon JH, Choi YJ, Cha SW, et al. Antimetastatic effects of ginsenoside Rd via inactivation of MAPK signaling and induction of focal adhesion formation［J］. Phytomedicine, 2012, 19(3-4): 284-292. ［10］ Ming Y, Chen Z, Chen L, et al. Ginsenoside compound K attenuates metastatic growth of hepatocellular carcinoma, which is associated with the translocation of nuclear factorκB p65 and reduction of matrix metalloproteinase2/9［J］. Planta Med, 2011, 77(5): 428-433. ［11］ Shi Q, Li J, Feng Z, et al. Effect of ginsenoside Rh2 on the migratory ability of HepG2 liver carcinoma cells: recruiting histone deacetylase and inhibiting activator protein 1 transcription factors［J］. Mol Med Rep, 2014, 10(4): 1779-1785. ［12］ Ho YL, Li KC, Chao W, et al. Korean red ginseng suppresses metastasis of human hepatoma SKHep1 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen activator［J］. Evid Based Complement Alternat Med, 2012, 2012: 965846. ［13］ Lee YS, Lee DG, Lee JY, et al. A formulated red ginseng extract upregulates CHOP and increases TRAILmediated cytotoxicity in human hepatocellular carcinoma cells［J］. Int J Oncol, 2013, 43(2): 591-599. ［14］ Lee JY, Jung KH, Morgan MJ, et al. Sensitization of TRAILinduced cell death by 20(S)ginsenoside Rg3 via CHOPmediated DR5 upregulation in human hepatocellular carcinoma cells［J］. Mol Cancer Ther, 2013, 12(3): 274-285. ［15］ Kim DG, Jung KH, Lee DG, et al. 20(S)Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin［J］. Oncotarget, 2014, 5(12): 4438-4451. ［16］ Li Q, Li Y, Wang X, et al. Cotreatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release［J］. Mol Carcinog, 2011, 50(10): 760-769. ［17］ Yu Y, Zhang C, Liu L, et al. Hepatic arterial administration of ginsenoside Rg3 and transcatheter arterial embolization for the treatment of VX2 liver carcinomas［J］. Exp Ther Med, 2013, 5(3): 761-766. ［18］ Kim SJ, Yuan HD, Chung SH. Ginsenoside Rg1 suppresses hepatic glucose production via AMP-activated protein kinase in HepG2 cells［J］. Biol Pharm Bull, 2010, 33(2): 325-328. ［19］ Yuan HD, Kim do Y, Quan HY, et al. Ginsenoside Rg2 induces orphan nuclear receptor SHP gene expression and inactivates GSK3β via AMPactivated protein kinase to inhibit hepatic glucose production in HepG2 cells［J］. Chem Biol Interact, 2012, 195(1): 35-42. ［20］ Wu R, Ru Q, Chen L, et al. Stereospecificity of ginsenoside Rg3 in the promotion of cellular immunity in hepatoma H22bearing mice［J］. J Food Sci, 2014, 79(7): H1430-1435.

[1]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[2]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[3]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[4]	向玉玲, 谭佳杰, 熊远果, 赵丽蓉, 黎晨, 张洪. 脱水淫羊藿素对肝癌细胞增殖、迁移和凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(9): 513-519.
[5]	李佳璇, 封颖璐. 糖皮质激素受体在肝癌细胞生长中的作用机制[J]. 国际肿瘤学杂志, 2023, 50(4): 241-243.
[6]	和婷, 王希, 张惠中, 刘昕阳, 王会平, 董轲. 血清TIM-3对肝癌患者诊断价值的研究[J]. 国际肿瘤学杂志, 2022, 49(9): 537-542.
[7]	张玉敏, 赵现伟, 何前进, 陈杰能. 超声造影联合血清CXCL8、CXCR2在原发性肝癌经导管动脉化疗栓塞术后疗效评估中的价值分析[J]. 国际肿瘤学杂志, 2022, 49(10): 592-596.
[8]	狄伟华, 赵雪梅. DNA损伤修复在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 635-638.
[9]	杜佳航, 陈栋, 陈耀庭. 三氧化二砷抗肝癌机制及其在肝癌治疗中的研究[J]. 国际肿瘤学杂志, 2021, 48(9): 572-.
[10]	韩保俊. 组蛋白乙酰转移酶P300在肝癌组织中的表达及其临床意义[J]. 国际肿瘤学杂志, 2021, 48(7): 415-419.
[11]	张玉元, 李臻, 詹鹏超, 李鑫, 叶书文, 王彩鸿, 刘杨. 肝癌标志物研究进展[J]. 国际肿瘤学杂志, 2021, 48(4): 241-245.
[12]	熊琳, 张修云, 张小余, 黎越, 徐细明. IWR-1-endo通过抑制Wnt通路影响肝癌细胞的迁移和增殖[J]. 国际肿瘤学杂志, 2021, 48(12): 711-715.
[13]	刘俊国, 张金卷, 王毅军. ALPPS中肝脏离断技术变异的临床应用进展[J]. 国际肿瘤学杂志, 2020, 47(8): 492-495.
[14]	张伟, 殷海涛, 周冲, 李向阳, 郭林. 甲磺酸阿帕替尼联合卡瑞利珠单抗治疗原发性肝癌伴肺转移一例[J]. 国际肿瘤学杂志, 2020, 47(8): 510-512.
[15]	辛瑞强, 宋晓萍, 张帆, 孙莹, 王涛, 孙伟. SUMO调控XBP1介导的内质网应激对肝癌进展的影响机制[J]. 国际肿瘤学杂志, 2020, 47(7): 397-403.